Avalo Therapeutics (NASDAQ:AVTX) Now Covered by Leerink Partners

Equities researchers at Leerink Partners began coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research note issued to investors on Monday,Benzinga reports. The firm set an “outperform” rating and a $38.00 price target on the stock. Leerink Partners’ price objective points to a potential upside of 101.70% from the company’s current price.

A number of other equities research analysts also recently issued reports on AVTX. Citizens Jmp decreased their price target on shares of Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating on the stock in a research note on Thursday, May 14th. Citigroup reissued an “outperform” rating on shares of Avalo Therapeutics in a research note on Wednesday, May 6th. HC Wainwright reduced their target price on shares of Avalo Therapeutics from $40.00 to $35.00 and set a “buy” rating on the stock in a report on Thursday, May 14th. Wall Street Zen upgraded shares of Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, March 29th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $60.00 price target (up from $48.00) on shares of Avalo Therapeutics in a report on Monday, May 11th. Thirteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $45.80.

Avalo Therapeutics Stock Performance

NASDAQ:AVTX opened at $18.84 on Monday. The business’s 50-day moving average is $16.34 and its 200 day moving average is $16.07. Avalo Therapeutics has a 12 month low of $4.61 and a 12 month high of $24.27. The company has a market capitalization of $990.42 million, a P/E ratio of -3.45 and a beta of 0.78.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.02. On average, research analysts forecast that Avalo Therapeutics will post -2.58 earnings per share for the current year.

Insider Buying and Selling

In other Avalo Therapeutics news, insider Paul Varki sold 75,063 shares of Avalo Therapeutics stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the completion of the sale, the insider directly owned 3,634 shares of the company’s stock, valued at $73,297.78. The trade was a 95.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 1,450 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $18.00, for a total value of $26,100.00. Following the completion of the sale, the insider directly owned 51,776 shares of the company’s stock, valued at $931,968. The trade was a 2.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 93,428 shares of company stock valued at $1,762,722 in the last 90 days. Company insiders own 4.46% of the company’s stock.

Institutional Investors Weigh In On Avalo Therapeutics

Large investors have recently bought and sold shares of the company. UBS Group AG grew its position in Avalo Therapeutics by 956.9% during the fourth quarter. UBS Group AG now owns 477,816 shares of the company’s stock valued at $8,677,000 after buying an additional 432,608 shares during the period. Moody Aldrich Partners LLC acquired a new position in shares of Avalo Therapeutics in the fourth quarter worth about $2,419,000. Nan Fung Trinity HK Ltd. acquired a new position in shares of Avalo Therapeutics in the fourth quarter worth about $3,432,000. Cantor Fitzgerald L. P. purchased a new stake in shares of Avalo Therapeutics during the 3rd quarter worth about $1,083,000. Finally, Boothbay Fund Management LLC boosted its stake in shares of Avalo Therapeutics by 1,916.6% during the 3rd quarter. Boothbay Fund Management LLC now owns 228,297 shares of the company’s stock worth $2,902,000 after acquiring an additional 216,976 shares in the last quarter. Hedge funds and other institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.